Pacira | PCRX - Selling And Administration Expenses


Pacira reported $91.8M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Assertio Holdings USD 16.73M 1.66M Sep/2024
Astellas Pharma JPY 221.78B 14.94B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Coherus Biosciences USD 26.02M 8.57M Mar/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.75B 831M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025
Xoma USD 11M 2.54M Jun/2024
Zoetis USD 619M 40M Dec/2025